{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:29:10Z","timestamp":1768372150208,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["013-2011-1-E00060"],"award-info":[{"award-number":["013-2011-1-E00060"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK077703"],"award-info":[{"award-number":["DK077703"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["WCU 200900000000024"],"award-info":[{"award-number":["WCU 200900000000024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.jconrel.2012.06.010","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T21:33:41Z","timestamp":1339709621000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model"],"prefix":"10.1016","volume":"162","author":[{"given":"Pyung-Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2012.06.010_bb0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4093\/dmj.2011.35.4.317","article-title":"Polymeric gene delivery for diabetic treatment","volume":"35","author":"Kim","year":"2011","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1074\/jbc.M209423200","article-title":"Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis","volume":"278","author":"Li","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0015","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1210\/en.2010-0115","article-title":"Minireview: update on incretin biology: focus on glucagon-like peptide-1","volume":"151","author":"Brubaker","year":"2010","journal-title":"Endocrinology"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2012.06.010_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1463-1326.2011.01457.x","article-title":"The future of incretin-based therapy: novel avenues\u2013novel targets","volume":"13","author":"Ahren","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2009.06.002","article-title":"Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors","volume":"124","author":"Verspohl","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/db08-0799","article-title":"Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease","volume":"58","author":"Martin","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0045","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1021\/bc200132t","article-title":"In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor","volume":"22","author":"Wu","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jcp.2006.043232","article-title":"Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1","volume":"61","author":"Ranganath","year":"2008","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/13543784.17.6.845","article-title":"Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes","volume":"17","author":"Mikhail","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/vhrm.2006.2.1.69","article-title":"Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes","volume":"2","author":"Schnabel","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0065","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/endo.141.6.7490","article-title":"Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats","volume":"141","author":"Szayna","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0070","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/bc100143c","article-title":"Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy","volume":"21","author":"Kim","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0075","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2337\/db06-1182","article-title":"Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis","volume":"56","author":"Lee","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0080","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.biomaterials.2010.10.045","article-title":"Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.peptides.2011.04.001","article-title":"GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1","volume":"32","author":"Li","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0090","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biomaterials.2008.10.009","article-title":"Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems","volume":"30","author":"Kim","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0095","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2009.11.043","article-title":"The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy","volume":"31","author":"Kim","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2011.09.072","article-title":"Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer","volume":"157","author":"Kim","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/10611860902718664","article-title":"Enhanced protection of Ins-1 beta cells from apoptosis under hypoxia by delivery of DNA encoding secretion signal peptide-linked exendin-4","volume":"17","author":"Ah Kim","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0110","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ymthe.2005.03.039","article-title":"Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes","volume":"12","author":"Choi","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0169-409X(97)00110-5","article-title":"Polylysine-based transfection systems utilizing receptor-mediated delivery","volume":"30","author":"Wagner","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0120","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jcem.87.3.8337","article-title":"The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes","volume":"87","author":"Egan","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/meta.2001.22519","article-title":"Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro","volume":"50","author":"Parkes","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0135","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2012.06.010_bb0140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1590\/S0004-27302008000600016","article-title":"Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes","volume":"52","author":"Davidson","year":"2008","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.jconrel.2012.06.010_bb0145","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1016\/j.biomaterials.2011.08.066","article-title":"Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365912005032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365912005032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:25:29Z","timestamp":1759159529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365912005032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0168365912005032"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2012.06.010","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2012.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}